Latest Allergy News From Medical News Today.

© Copyright 2008 Medical News Today

CYT003-QbG10 Monotherapy For The Treatment Of Allergic Diseases Is Safe And Efficacious In Placebo-Controlled Phase II Study
Cytos Biotechnology Ltd (SWX:CYTN) announced results from two randomized, double-blind, placebo-controlled, multicentre phase II studies with CYT003-QbG10 monotherapy for the treatment of house dust mite and cat allergy, and with CYT005-AllQbG10 combination therapy for the treatment of house dust mite allergy.

Aggressive Treatment Of Childhood Eczema Could Help Prevent Asthma, Says New Study
The study, published online in the Journal of Allergy and Clinical Immunology, calls for trials of aggressive therapies against childhood eczema in attempt to reduce the incidence of asthma in later life. The study, conducted by the University of Melbourne, Monash University and Menzies Research Institute in Tasmania, has followed more than 8500 people who are part of the Tasmanian Longitudinal Health Study from the ages of seven to 44.

Finding That Could Shed Light On Golden Staph, Candida And Allergies
Recent scientific findings explain why patients with a rare immunodeficiency disorder are unusually susceptible to certain common infections. By revealing the exact molecular mechanisms involved, they also give us clues as to why some 'healthy' people are more prone to these infections than others, and suggest potential treatments.

Greer Completes Enrollment For Pivotal Phase III Trial Evaluating The Efficacy Of Sublingual-Oral Immunotherapy For Treating Short Ragweed Allergies
Greer, a leading developer and provider of allergy immunotherapy products and services, has completed enrollment for its pivotal Phase III clinical trial designed to study the efficacy of sublingual-oral immunotherapy (SLIT) as a treatment for adults with allergic rhinoconjunctivitis caused by short ragweed pollen. It is estimated that 30 million Americans are allergic to short ragweed pollen, making it one of the most common allergens.